Drug Profile


Alternative Names: BI-201335; BI-201335-NA; BI-201335-sodium; BI-201335Na; Faldaprevir-sodium

Latest Information Update: 25 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Trek Therapeutics
  • Class Amides; Antivirals; Carboxylic acids; Cyclopropanes; Oligopeptides; Pyrrolidines; Quinolines; Small molecules; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Sep 2017 Trek Therapeutics completes a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand and USA (PO) (NCT02716428)
  • 14 Feb 2017 Efficacy and adverse events data from a phase IIa trial in Hepatitis C released by Trek Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top